[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351829-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351829-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","constitutional-brca1-promoter-methylation-in-patients-with-ovarian-cancer-results-of-the-observational-ago-tr1-study","Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer - Results of the Observational AGO-TR1 Study","","Constitutional epimutations arise early in development and persist across normal tissues, including peripheral blood. Constitutional BRCA1 promoter methylation has emerged as a risk factor and potential biomarker for BRCA1-associated cancers such as ovarian cancer (OC). This retrospective study assessed the clinical relevance of constitutional BRCA1 promoter methylation in 473 OC patients enrolled in the observational AGO-TR1 study.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/constitutional-brca1-promoter-methylation-in-patients-with-ovarian-cancer-results-of-the-observational-ago-tr1-study/351829/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/constitutional-brca1-promoter-methylation-in-patients-with-ovarian-cancer-results-of-the-observational-ago-tr1-study/351829.png","ImageObject",300,407,{"name":42,"@type":43},"Aran","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is constitutional BRCA1 promoter methylation and why is it relevant to ovarian cancer?","Question",{"text":63,"@type":64},"It is an epigenetic change present early in development and detectable across normal tissues, including blood. It has been proposed as a risk factor and potential biomarker for BRCA1-associated ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was constitutional BRCA1 promoter methylation measured in this study?",{"text":68,"@type":64},"BRCA1 promoter methylation was quantified using methylation-specific realtime PCR on whole blood-derived DNA, with methylation levels of at least 1.0% defined as methylation-positive.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings regarding detection rates and clinical associations?",{"text":72,"@type":64},"BRCA1 promoter methylation was detected in 42 of 473 OC patients and 26 of 476 controls. Positive patients were diagnosed at a younger median age, showed a correlation with tumor methylation, and tumor methylation in some samples was attributable to constitutional methylation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351829,1790283341,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Reports | Cancer Genetics  \nConstitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study  \nMohamad Kayali, BSc1; Eric Hahnen, PhD1  ; Alexander Burges, MD2  ; Alexander Reuss, PhD3  ; Julia Caro-Valenzuela, MSc1  ;  \nNikolaus de Gregorio, MD4; Florian Heitz, MD5  ; Sandra Schmidt1; Frederik Marm, MD6  ; Felix Hilpert, MD7,8  ; Pauline Wimberger, MD9  ; Stefan Kommoss, MD10; Katharina Prieske, MD8,11; Christoph Engel, MD12,13  ; Paul Buderath, MD14; Dimo Dietrich, MD15  ; Rita Schmutzler, MD1; Jalid Sehouli, MD16  ; Kerstin Rhiem, MD1; Philipp Harter, MD5  ; and Jan Hauke, PhD1   \nDOI [https://doi.org/10.1200/PO-25-01230](https://doi.org/10.1200/PO-25-01230)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | Constitutional epimutations arise early in development and are present across normal tissues, including peripheral blood. Constitutional BRCA1 promoter methylation has emerged as a risk factor for BRCA1-associated cancers, such as ovarian cancer (OC), and may serve as a biomarker for OC risk. This study retrospectively evaluated the clinical relevance of constitutional BRCA1 promoter methylation in 473 patients with OC enrolled in the observational AGO-TR1 study ([ClinicalTrials.gov](ClinicalTrials.gov) identiﬁer: NCT02222883) . |\n| MATERIALS\u003Cbr>AND METHODS | BRCA1 promoter methylation was quantiﬁed by the methylation-speciﬁc realtime polymerase chain reaction using whole blood-derived DNA from 476 female controls and 473 patients with OC along with 473 corresponding tumorderived DNA samples. Methylation levels ≥1.0% were considered methylationpositive. |\n| RESULTS | BRCA1 promoter methylation in blood-derived DNA was detected in 42 of 473 patients with OC and in 26 of 476 controls (8.9% v 5.5%; odds ratio [OR], 1.69 [95% CI, 1.02 to 2.80], P 5 .0432), with the strongest association observed with methylation levels ≥10%(OR, 6.17 [95% CI, 1.37 to 27.72], P 5 .018) . Patients with BRCA1 promoter methylation in blood-derived DNA were diagnosed at a younger median age than those without (54.0 v 60.0 years, P 5 .018) . Constitutional BRCA1 promoter methylation was less frequent in patients carrying pathogenic germline variants in OC predisposition genes than in noncarriers (4 .1% v 10. 5%; OR, 0.37 [95% CI, 0.14 to 0. 96], P 5 . 04) and showed no association with a family history of cancer or platinum-based chemotherapy before blood draw. BRCA1 promoter methylation in blood-derived DNA was correlated with tumor BRCA1 promoter methylation (P \u003C .001) . Tumor BRCA1 promoter methylation was observed in 64 of 473 samples (13.5%), half (32 of 64) of which were attributable to constitutional BRCA1 promoter methylation also detectable in the blood. |\n| CONCLUSION | Constitutional BRCA1 promoter methylation accounts for a substantial proportion of OCs and represents a robust biomarker for individual OC risk. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \nAccepted May 14, 2026 Published June 12, 2026  \nJCO Precis Oncol 10:e2501230 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nWomen carrying pathogenic germline variants (PGVs) in BRCA1 , BRCA2 , BRIP1 , PALB2 , RAD51C, and RAD51D are at an increased risk for ovarian cancer (OC) compared with the general female population.1-3 In addition, OC is part of the tumor spectrum of the Lynch syndrome, and women with PGVs in MLH1 , MSH2 , and MSH6 are at an elevated OC risk.4 Up to 20% of patients with OC carry heterozygous PGVs in BRCA1/2 , and up to 5% carry PGVs in further OC  \npredisposition genes.5,6 A proportion of OCs may additionally be explained by unfavorable OC-speciﬁc polygenic risk scores (PRSs).3,7 However, the majority ofunselected OCs are not caused by known heritable risk factors such as PGVs in established OC predisposition genes or PRSs. Pathogenic somatic variants (PSVs) in OC predisposition genes and BRCA1 promoter methylati","cbCaih19XRVyXWMb","https://ap.wps.com/l/cbCaih19XRVyXWMb","pdf",3811866,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What is constitutional BRCA1 promoter methylation and why is it relevant to ovarian cancer?\",\"answer\":\"It is an epigenetic change present early in development and detectable across normal tissues, including blood. It has been proposed as a risk factor and potential biomarker for BRCA1-associated ovarian cancer.\"},{\"question\":\"How was constitutional BRCA1 promoter methylation measured in this study?\",\"answer\":\"BRCA1 promoter methylation was quantified using methylation-specific realtime PCR on whole blood-derived DNA, with methylation levels of at least 1.0% defined as methylation-positive.\"},{\"question\":\"What were the main findings regarding detection rates and clinical associations?\",\"answer\":\"BRCA1 promoter methylation was detected in 42 of 473 OC patients and 26 of 476 controls. Positive patients were diagnosed at a younger median age, showed a correlation with tumor methylation, and tumor methylation in some samples was attributable to constitutional methylation.\"}]","Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer - Results of the Observational AGO-TR1 Study | PDF",1790096194,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f8399583553da9f76ee8d86c5183004.webp",983,1315,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/942f07a70bb13d2b1fd40bf48b12eef8.webp",982,1314,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a22487c1f75ca87a5ed3da69b4733055.webp",981,1312,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6f46d90d83ba6805582cd1a082bfc74.webp",980,1311]